A Retrospective Analysis of the Epidemiology and Hospital Utilization in Waldenströms Macroglobulinemia: NIS 2023 Study
Waldenström macroglobulinemia (WM) is a rare, indolent, IgM‑producing lymphoplasmacytic lymphoma that predominantly affects older adults. In this study, we characterize contemporary demographic patterns and epidemiology of WM using national inpatient data to better define the current inpatient burden of this disease.
Materials and Methods/Case Presentation/Objective:
The NIS 2023 database was used to obtain data regarding hospitalizations with WM. Epidemiological data healthcare utilization, and clinical outcome were measured using comparative statistical analysis. P< .05.
Results/Description/Main Outcome Measure(s):
Total hospitalizations with WM were 1570. The average age is 76.6 years, standard error (SE) .23, P=.002. Length of Stay (LOS) 6.3 days. Average total charge was $95435.45, Inpatient mortality was 4.27%. Hospital types include, Rural hospital 7.45%, urban non-teaching 4.46%, urban teaching 78.09%. Insurance status includes Medicare 86.5%, private insurance 10%, Medicaid is 1.6%, self-pay .4%, others 1.5%.
Conclusion(s).:
Waldenström macroglobulinemia (WM) is an uncommon, typically indolent lymphoplasmacytic lymphoma, and contemporary real‑world data on its inpatient burden remain limited. In this nationally representative analysis, we describe current demographic patterns, epidemiology, and clinical outcomes of hospitalized WM patients, demonstrating that despite the rarity of the disease, a subset of predominantly older adults experiences substantial morbidity requiring acute care. These findings highlight the need for improved risk stratification and outpatient management strategies to potentially mitigate preventable hospitalizations and decrease cost burden.
Trademarked Items:
References:
